Angela is an International Cooperation Officer at the Health Intervention and Technology Assessment Program Foundation (HITAP), where she supports global partnerships and coordination of regional networks and platforms such as HTAsiaLink, SAPPHIRE, and GEAR. With a strong interest in bridging technical research and policy, she also contributes to r

In January 2019, the Minister of Health from Chhattisgarh state, India, reached out to International Health Policy Program (IHPP), a semi-autonomous research program in Thailand, to learn about the Thai experience of implementing Universal Health Coverage (UHC). The minister requested to meet with s

Patient’s perspectives can offer great insights into perceived benefits of health interventions and the challenges and obstacles encountered as a result of the healthcare system. Now at its 10th issue, the HTAsiaLink Newsletter focuses on the theme of Patient Involvement in Health Technology Assessm

As more countries provide free health care, pharmaceutical reimbursement lists are becoming a concern, especially in low- and middle-income countries. In 2007, Nepal decreed that health is a human right and began basic health coverage for a target group of the poor, destitute, elderly, and disabled.

Achieving universal health coverage (UHC) requires policy initiatives supported by long-term system reform and an accountable governance structure that can sustainably deliver all three dimensions of UHC, population coverage, breadth of benefits package, and degree of financial coverag

Presently, Cost-Effectiveness Analysis has been increasingly adopted in health technology assessment. In addition, it is recognized as an important tool for policy makers in the health care resource allocation decision making process. However, the presentation of Cost-Effectiveness Analysis results in terms of cost per Quality-Adjusted Life Year (Q

Abstract Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. I

SUMMARY POINTS •  End stage renal disease (ESRD) is a life-threatening condition that results in most patients requiring a lifetime of high cost renal dialysis •  Governments have grappled with the political, economic, and ethical challenges of providing treatment with their available budgets •

People with hearing loss who are registered under the Universal Health Coverage scheme areeligible to receive hearing aids from hospitals free-of-charge. However, the costs associated with this policy after having received the hearing aids must still be borne by users such as hearing aid maintenance

Hialy Gutierrez, MPH,1,2 Ashwini Shewade, MS, MSc,1 Minghan Dai, MPH,1 Pedro Mendoza-Arana, MD, MSc,3 Octavio Go´mez-Dante´s, MD, MPH,4 Nishant Jain, PhD,5 Irma Khonelidze, MPA,6 Juliet Nabyonga-Orem, MD, MSc,7 Karima Saleh, PhD,8 Yot Teerawattananon, MD, PhD,9 Sania Nishtar, SI, PhD,10 and John Hor